Literature DB >> 30635285

Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy.

Paul J Orchard1, David R Nascene2, Weston P Miller3, Ashish Gupta1, Dan Kenney-Jung4, Troy C Lund1.   

Abstract

Adrenoleukodystrophy (ALD) is caused by mutations within the X-linked ABCD1 gene, resulting in the inability to transport acylated very long chain fatty acids (VLCFAs) into the peroxisome for degradation. VLCFAs subsequently accumulate in tissues, including the central nervous system. Up to 40% of boys develop a severe progressive demyelinating form of ALD, cerebral ALD, resulting in regions of demyelination observed on brain magnetic resonance imaging that are associated with a "garland ring" of gadolinium contrast enhancement. Gadolinium enhancement indicates blood-brain barrier (BBB) disruption and an active inflammatory disease process. Only hematopoietic cell transplant (HCT) has been shown to halt neurologic progression, although the mechanism of disease arrest is unknown. We evaluated imaging- and transplant-related biomarkers in 66 males who underwent HCT. In 77% of patients, gadolinium contrast resolved by 60 days post-HCT. We determined that time to neutrophil recovery and extent of donor chimerism correlated significantly with time to contrast resolution post-HCT. Graft failure was associated with a significantly slower rate of contrast resolution (P < .0001). Time to neutrophil recovery remained significant in multivariate analysis with other biomarkers (P = .03). Our data suggest that robust donor myeloid recovery is necessary for timely repair of the BBB.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30635285      PMCID: PMC6440119          DOI: 10.1182/blood-2018-11-887240

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Effects of myeloablation, peripheral chimerism, and whole-body irradiation on the entry of bone marrow-derived cells into the brain.

Authors:  Antoine Lampron; Martine Lessard; Serge Rivest
Journal:  Cell Transplant       Date:  2011-09-22       Impact factor: 4.064

2.  Umbilical Cord Blood Expansion: Are We There Yet?

Authors:  Troy C Lund
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-10       Impact factor: 5.742

Review 3.  X-linked adrenoleukodystrophy: pathogenesis and treatment.

Authors:  Marc Engelen; Stephan Kemp; Bwee-Tien Poll-The
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

4.  Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report.

Authors:  Weston P Miller; Steven M Rothman; David Nascene; Teresa Kivisto; Todd E DeFor; Richard S Ziegler; Julie Eisengart; Kara Leiser; Gerald Raymond; Troy C Lund; Jakub Tolar; Paul J Orchard
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

5.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.

Authors:  John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

6.  Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation.

Authors:  Fiona L Wilkinson; Ana Sergijenko; Kia J Langford-Smith; Marcela Malinowska; Rob F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

7.  Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.

Authors:  Nathalie Cartier; Salima Hacein-Bey-Abina; Cynthia C Bartholomae; Gabor Veres; Manfred Schmidt; Ina Kutschera; Michel Vidaud; Ulrich Abel; Liliane Dal-Cortivo; Laure Caccavelli; Nizar Mahlaoui; Véronique Kiermer; Denice Mittelstaedt; Céline Bellesme; Najiba Lahlou; François Lefrère; Stéphane Blanche; Muriel Audit; Emmanuel Payen; Philippe Leboulch; Bruno l'Homme; Pierre Bougnères; Christof Von Kalle; Alain Fischer; Marina Cavazzana-Calvo; Patrick Aubourg
Journal:  Science       Date:  2009-11-06       Impact factor: 47.728

8.  Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.

Authors:  Florian Eichler; Christine Duncan; Patricia L Musolino; Paul J Orchard; Satiro De Oliveira; Adrian J Thrasher; Myriam Armant; Colleen Dansereau; Troy C Lund; Weston P Miller; Gerald V Raymond; Raman Sankar; Ami J Shah; Caroline Sevin; H Bobby Gaspar; Paul Gissen; Hernan Amartino; Drago Bratkovic; Nicholas J C Smith; Asif M Paker; Esther Shamir; Tara O'Meara; David Davidson; Patrick Aubourg; David A Williams
Journal:  N Engl J Med       Date:  2017-10-04       Impact factor: 91.245

9.  Elevated cerebral spinal fluid cytokine levels in boys with cerebral adrenoleukodystrophy correlates with MRI severity.

Authors:  Troy C Lund; Paul S Stadem; Angela Panoskaltsis-Mortari; Gerald Raymond; Weston P Miller; Jakub Tolar; Paul J Orchard
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

10.  Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy.

Authors:  Paul J Orchard; Troy Lund; Wes Miller; Steven M Rothman; Gerald Raymond; David Nascene; Lisa Basso; James Cloyd; Jakub Tolar
Journal:  J Neuroinflammation       Date:  2011-10-20       Impact factor: 8.322

View more
  10 in total

1.  Oxygen-Glucose Deprivation/Reoxygenation-Induced Barrier Disruption at the Human Blood-Brain Barrier is Partially Mediated Through the HIF-1 Pathway.

Authors:  Shyanne Page; Snehal Raut; Abraham Al-Ahmad
Journal:  Neuromolecular Med       Date:  2019-03-26       Impact factor: 3.843

Review 2.  Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases.

Authors:  Katsutsugu Umeda
Journal:  Int J Hematol       Date:  2022-05-14       Impact factor: 2.490

Review 3.  Hematopoietic Stem Cell Transplantation for Neurological Disorders: A Focus on Inborn Errors of Metabolism.

Authors:  Pedro de Vasconcelos; João F Lacerda
Journal:  Front Cell Neurosci       Date:  2022-05-26       Impact factor: 6.147

4.  trans-2-Enoyl-CoA Reductase Tecr-Driven Lipid Metabolism in Endothelial Cells Protects against Transcytosis to Maintain Blood-Brain Barrier Homeostasis.

Authors:  Jinxuan Wang; Jianxiong Xu; Guangchao Zang; Tao Zhang; Qi Wu; Hongping Zhang; Yidan Chen; Yi Wang; Weixi Qin; Shuang Zhao; Erdai Qin; Juhui Qiu; Xiaojuan Zhang; Lin Wen; Yeqi Wang; Guixue Wang
Journal:  Research (Wash D C)       Date:  2022-04-04

5.  Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy.

Authors:  Elizabeth I Pierpont; David R Nascene; Ryan Shanley; Daniel L Kenney-Jung; Richard S Ziegler; Weston P Miller; Ashish O Gupta; Troy C Lund; Paul J Orchard; Julie B Eisengart
Journal:  Neurology       Date:  2020-07-02       Impact factor: 9.910

6.  Chimerism in the Realm of Hematopoietic Stem Cell Transplantation for Non-malignant Disorders-A Perspective.

Authors:  Clare Zimmerman; Shalini Shenoy
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

7.  Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy.

Authors:  Isabelle Weinhofer; Paulus Rommer; Bettina Zierfuss; Patrick Altmann; Martha Foiani; Amanda Heslegrave; Henrik Zetterberg; Andreas Gleiss; Patricia L Musolino; Yi Gong; Sonja Forss-Petter; Thomas Berger; Florian Eichler; Patrick Aubourg; Wolfgang Köhler; Johannes Berger
Journal:  Nat Commun       Date:  2021-03-22       Impact factor: 14.919

8.  Evaluation of Neurofilament Light Chain as a Biomarker of Neurodegeneration in X-Linked Childhood Cerebral Adrenoleukodystrophy.

Authors:  Hongge Wang; Matthew D Davison; Martin L Kramer; Weiliang Qiu; Tatiana Gladysheva; Ruby M S Chiang; Can Kayatekin; David R Nascene; Leyla A Taghizadeh; Carina J King; Erin E Nolan; Ashish O Gupta; Paul J Orchard; Troy C Lund
Journal:  Cells       Date:  2022-03-07       Impact factor: 6.600

Review 9.  Taking Advantages of Blood-Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?

Authors:  Hugo Alarcan; Yara Al Ojaimi; Debora Lanznaster; Jean-Michel Escoffre; Philippe Corcia; Patrick Vourc'h; Christian R Andres; Charlotte Veyrat-Durebex; Hélène Blasco
Journal:  J Pers Med       Date:  2022-06-29

Review 10.  Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases.

Authors:  Robert J Hayashi
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.